Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi∗ZZ Genotype).
Fromme M, Payancé A, Mandorfer M, Thorhauge KH, Pons M, Miravitlles M, Stolk J, van Hoek B, Stirnimann G, Frankova S, Sperl J, Kremer AE, Burbaum B, Schrader C, Kadioglu A, Walkenhaus M, Schneider CV, Klebingat F, Balcar L, Kappe NN, Schaefer B, Chorostowska-Wynimko J, Aigner E, Gensluckner S, Striedl P, Roger P, Ryan J, Roche S, Vögelin M, Ala A, Bantel H, Verbeek J, Mariño Z, Praktiknjo M, Gevers TJG, Reuken PA, Berg T, George J, Demir M, Bruns T, Trautwein C, Zoller H, Trauner M, Genesca J, Griffiths WJ, Clark V, Krag A, Turner AM, McElvaney NG, Strnad P. Fromme M, et al. Among authors: demir m. Gastroenterology. 2024 Oct 15:S0016-5085(24)05572-0. doi: 10.1053/j.gastro.2024.10.010. Online ahead of print. Gastroenterology. 2024. PMID: 39414159 Free article.
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Traussnigg S, et al. Among authors: demir m. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22. Lancet Gastroenterol Hepatol. 2019. PMID: 31345778 Clinical Trial.
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.
Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Lang S, et al. Among authors: demir m. Gastroenterology. 2020 Nov;159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005. Epub 2020 Jul 9. Gastroenterology. 2020. PMID: 32652145 Free PMC article.
Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
Loosen SH, Schulze-Hagen M, Vucur M, Gorgulho J, Paffenholz P, Benz F, Mohr R, Demir M, Wree A, Kuhl C, Trautwein C, Tacke F, Bruners P, Luedde T, Roderburg C. Loosen SH, et al. Among authors: demir m. JGH Open. 2021 Feb 1;5(3):356-363. doi: 10.1002/jgh3.12501. eCollection 2021 Mar. JGH Open. 2021. PMID: 33732882 Free PMC article.
Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.
Loosen SH, Benz F, Mohr R, Reuken PA, Wirtz TH, Junker L, Jansen C, Meyer C, Praktiknjo M, Wree A, Reißing J, Demir M, Gu W, Vucur M, Schierwagen R, Stallmach A, Kunstein A, Bode J, Trautwein C, Tacke F, Luedde T, Bruns T, Trebicka J, Roderburg C. Loosen SH, et al. Among authors: demir m. JHEP Rep. 2024 Mar 4;6(5):101054. doi: 10.1016/j.jhepr.2024.101054. eCollection 2024 May. JHEP Rep. 2024. PMID: 38681861 Free PMC article.
1,450 results